Exact Sciences Corp (EXAS) - Company Total Revenue

Exact Sciences has historically adhered to strict medical protocols and the safe disposal of reagents. The company's current sales figures reflect genuine revenue stability, where the value of 3.25 serves as the target level. Looking ahead, profit growth will be driven by DNA hubs that reduce testing costs, as well as the optimization of logistics and IT services through external partners.

Cologuard - EXAS Revenue and Sales Volume (period 07/04/2022 - 04/04/2026)

Analytical breakdowns for Exact Sciences Corporation (EXAS)

- market value and analyst target forecast:

Market Chart Exact Sciences Inc.|EXAS - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Exact Sciences Corporation|EXAS - Real Price to Acquire Entire Company

- book value of equity indicators:

Equity per Share Exact Sciences|EXAS - Book Capitalization|Market Capitalization to Book Value Ratio exactsciences.com|EXAS - Company Total Assets

- debt obligations and liquidity statistics:

- financial results and valuation multiples details:

EXAS - Net Profit|Company Profit Forecast Exact Sciences|EXAS - P/E Multiple|Projected Price to Earnings Ratio exactsciences.com|EXAS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Exact Sciences Corporation|EXAS - Operating profit EBITDA|Net earnings per share for the last 12 months Exact Sciences|EXAS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months exactsciences.com|EXAS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Exact Sciences

- company sales and revenue statistics:

EXAS - Revenue and Sales Volume|Company Expected Sales Volume Exact Sciences Inc.|EXAS - Market Cap to Revenue|Market Cap to Projected Revenue Exact Sciences Corporation

General company analysis:Exact Sciences Inc. - EXAS

Exact Sciences implementation of innovative DNA tests for early cancer diagnosis converts directly into a daily revenue stream. This indicator captures daily sales volume, reflecting the business's operational activity in real time. By analyzing changes in the company's sales volume, an investor assesses the commercialization pace of liquid biopsy. Such dynamics allow for the differentiation of real growth from temporary fluctuations. A stable trend confirms the fundamental resilience of the asset's market value.

Analysis of competing companies